Top

Published in:

01-04-2019 | Fatigue | Original Communication

Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP

Authors: Emanuele Spina, Antonietta Topa, Rosa Iodice, Stefano Tozza, Lucia Ruggiero, Raffaele Dubbioso, Marcello Esposito, Pasquale Dolce, Lucio Santoro, Fiore Manganelli

Published in: Journal of Neurology | Issue 4/2019

Abstract

Objective

The current clinical measures (ONLS, R-ODS, mRS, and MRC) may not be so sensitive in capturing minimal variations or measuring fatigue in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Our aim was to assess if 6-min walk test (6MWT) is able to increase the sensitivity in detecting response to therapy and to capture fatigue in CIDP patients.

Methods

We tested 6MWT in 42 CIDP patients. Using both anchor-based and distribution-based approaches, we estimated the meaningful clinical change after therapy by calculating the minimum improvement cutoff (Minimal Clinically Important Difference Score—MCID) required for considering a patient as responder. We calculated the sensitivity of the 6MWT versus the other clinical outcomes. We analysed fatigue by comparing the velocities between first and sixth minutes of the 6MWT and the effect of treatment on fatigue using an ANOVA model for repeated measures.

Results

MCID resulted equal to 20 m. The combination of 6MWT-MCID cutoff with the other clinical measures led to identify 74% of responders. The sensitivity of the 6MWT was 90% versus 77% of the other clinical measures. The 6MWT was also sensitive in capturing fatigue-related changes, even though fatigue was not influenced by treatment.

Conclusions

The combination of the 6MWT with the other clinical measures increased the chance to detect the quote of responders. We propose to include the 6MWT in the routine assessment of CIDP patients and the MCID cutoff at 20 m could be set for identifying the responders and properly guiding the therapy management.

Merkies IS, Schmitz PI, van der Meché FG, van Doorn PA (2000) Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 54(4):943–949CrossRefPubMed

Graham RC, Hughes RA (2006) A modified peripheral neuropathy scale: the overall neuropathy limitations scale. J Neurol Neurosurg Psychiatry 77(8):973–976 (Epub 2006 Mar 30)CrossRefPubMedPubMedCentral

van Nes SI, Vanhoutte EK, van Doorn PA et al (2011) Rasch-built Overall Disability Scale (R-ODS) for immune-mediated peripheral neuropathies. Neurology 76(4):337–345. https://doi.org/10.1212/WNL.0b013e318208824b CrossRefPubMed

Bamford JM, Sandercock PA, Warlow CP, Slattery J (1989) Interobserver agreement for the assessment of handicap in stroke patients. Stroke 20(6):828 (No abstract available)CrossRefPubMed

Kleyweg RP, van der Meché FG, Schmitz PI (1991) Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain–Barré syndrome. Muscle Nerve 14(11):1103–1109CrossRefPubMed

Padua L, Pazzaglia C, Pareyson D et al (2016) CMT-TRIAAL Group. Novel outcome measures for Charcot-Marie-Tooth disease: validation and reliability of the 6-min walk test and StepWatch(™) Activity Monitor and identification of the walking features related to higher quality of life. Eur J Neurol 23(8):1343–1350. https://doi.org/10.1111/ene.13033 (Epub 2016 May 10)CrossRefPubMed

Pazzaglia C, Camerota F, Germanotta M, Di Sipio E, Celletti C, Padua L (2016 Jul) Efficacy of focal mechanic vibration treatment on balance in Charcot-Marie-Tooth 1A disease: a pilot study. J Neurol 263(7):1434–1441. https://doi.org/10.1007/s00415-016-8157-5 (Epub 2016 May 13)CrossRefPubMed

Bennett SE, Bromley LE, Fisher NM, Tomita MR, Niewczyk P (2017) Validity and reliability of four clinical gait measures in patients with multiple sclerosis. Int J MS Care 19(5):247–252. https://doi.org/10.7224/1537-2073.2015-006 CrossRefPubMedPubMedCentral

Angelini C, Semplicini C, Ravaglia S et al (2012) Italian Group on GSDII. New motor outcome function measures in evaluation of late-onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve 45(6):831–834. https://doi.org/10.1002/mus.23340 CrossRefPubMed

10.

Dunaway Young S, Montes J, Kramer SS et al (2016) Six-minute walk test is reliable and valid in spinal muscular atrophy. Muscle Nerve 54(5):836–842. https://doi.org/10.1002/mus.25120 (Epub 2016 May 13)CrossRefPubMed

11.

Fulk GD, Echternach JL, Nof L, O’Sullivan S (2008) Clinometric properties of the six-minute walk test in individuals undergoing rehabilitation poststroke. Physiother Theory Pract 24(3):195–204. https://doi.org/10.1080/09593980701588284 CrossRefPubMed

12.

Eichinger K, Heatwole C, Heininger S et al (2017) FSHD Clinical Trials Research Network. Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. Muscle Nerve 55(3):333–337. https://doi.org/10.1002/mus.25251 (Epub 2016 Dec 5)CrossRefPubMed

13.

McDonald CM, Henricson EK, Han JJ et al (2010) The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 42(6):966–974. https://doi.org/10.1002/mus.21808 CrossRefPubMed

14.

Kobayashi E, Himuro N, Takahashi M (2017) Clinical utility of the 6-min walk test for patients with moderate Parkinson’s disease. Int J Rehabil Res 40(1):66–70. https://doi.org/10.1097/MRR.0000000000000205 CrossRefPubMed

15.

Jaeschke R, Singer J, Guyatt GH (1989) Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 10(4):407–415CrossRef

16.

Copay AG, Subach BR, Glassman SD, Polly DW Jr, Schuler TC (2007) Understanding the minimum clinically important difference: a review of concepts and methods. Spine J 7(5):541–546 (Epub 2007 Apr 2. Review)CrossRef

17.

Joint Task Force of the EFNS and the PNS. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies (2010) Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society–first revision. J Peripher Nerv Syst 15(3):185–195. https://doi.org/10.1111/j.1529-8027.2010.00278.x CrossRef

18.

ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111-117 (No abstract available. Erratum in: Am J Respir Crit Care Med. 2016 May 15;193(10):1185)

19.

Nobile-Orazio E, Cocito D, Jann S et al (2015) IMC Trial Group. Frequency and time to relapse after discontinuing 6-month therapy with IVIg or pulsed methylprednisolone in CIDP. J Neurol Neurosurg Psychiatry 86(7):729–734. https://doi.org/10.1136/jnnp-2013-307515 (Epub 2014 Sep 22)CrossRefPubMed

20.

Merkies IS, van Nes SI, Hanna K, Hughes RA, Deng C (2010) Confirming the efficacy of intravenous immunoglobulin in CIDP through minimum clinically important differences: shifting from statistical significance to clinical relevance. J Neurol Neurosurg Psychiatry 81(11):1194–1199. https://doi.org/10.1136/jnnp.2009.194324 (Epub 2010 Jul 20)CrossRefPubMed

21.

Wright A, Hannon J, Hegedus EJ, Kavchak AE (2012) Clinimetrics corner: a closer look at the minimal clinically important difference (MCID). J Man Manip Ther 20(3):160–166. https://doi.org/10.1179/2042618612Y.00000000001 CrossRefPubMedPubMedCentral

22.

Hughes RA, Lunn MP (2016) Regarding the past, what is the trial you have always been dreaming of in CIDP? Rev Neurol (Paris) 172(10):620–626. https://doi.org/10.1016/j.neurol.2016.07.020 (Epub 2016 Sep 13. Review)CrossRef

23.

Montes J, McDermott MP, Martens WB et al (2010) Muscle Study Group and the Pediatric Neuromuscular Clinical Research Network. Six Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy, Neurology 74(10):833–838. https://doi.org/10.1212/WNL.0b013e3181d3e308

24.

Goldman MD, Marrie RA, Cohen JA (2008) Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 14(3):383–390 (Epub 2007 Oct 17)

25.

Pera MC, Luigetti M, Pane M et al (2017) 6MWT can identify type 3 SMA patients with neuromuscular junction dysfunction. Neuromuscul Disord 27(19):879–882. https://doi.org/10.1016/j.nmd.2017.07.007 (Epub 2017 Jul 14)CrossRefPubMed

26.

Gilmore KJ, Allen MD, Dhoerty TJ, Kimpinski K, Rice CL (2017) Electrophysiological and neuromuscolar stability of persons with chronic inflammatory demylinating polyneuropathy. Muscle Nerve 56(3):413–420. https://doi.org/10.1002/mus.25516 (Epub 2017 Mar 23)CrossRefPubMed

Title: Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP
Authors: Emanuele Spina
Antonietta Topa
Rosa Iodice
Stefano Tozza
Lucia Ruggiero
Raffaele Dubbioso
Marcello Esposito
Pasquale Dolce
Lucio Santoro
Fiore Manganelli
Publication date: 01-04-2019
Publisher: Springer Berlin Heidelberg
Keyword: Fatigue
Published in: Journal of Neurology / Issue 4/2019
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-019-09207-1

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP

Abstract

Objective

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

Correction to: Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults

Changing epidemiology of motor neurone disease in Scotland

Sleep disturbances are common in patients with autoimmune encephalitis

Clinical and neuroimaging investigations of language disturbance in frontotemporal dementia–motor neuron disease patients

Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France

Individual parkinsonian motor signs and striatal dopamine transporter deficiency: a study with [I-123]FP-CIT SPECT